Aclaris Therapeutics, Inc. (NasdaqGS:ACRS) announced that it is conducting a strategic review of its business to determine how to optimally deploy its capital to maximize shareholder return. On a preliminary unaudited basis, as of December 31, 2023, Aclaris? aggregate cash, cash equivalents and marketable securities was approximately $182 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.34 USD | +2.29% | +10.74% | +27.62% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.62% | 95.49M | |
+21.74% | 46.4B | |
-0.97% | 41.75B | |
+49.56% | 41.37B | |
-3.52% | 29.71B | |
+11.12% | 26.01B | |
-19.37% | 19.52B | |
+31.18% | 12.43B | |
-0.04% | 12.13B | |
+0.39% | 12.18B |
- Stock Market
- Equities
- ACRS Stock
- News Aclaris Therapeutics, Inc.
- Aclaris Therapeutics Conducts Strategic Review of Business